360 related articles for article (PubMed ID: 10999043)
21. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
22. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
23. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
25. A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer.
Kouroussis C; Kalbakis K; Androulakis N; Agelaki S; Vamvakas L; Malas K; Souglakos J; Vardakis N; Georgoulias V
Anticancer Res; 2004; 24(6):4217-21. PubMed ID: 15736475
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
Rosati G; Rossi A; Tucci A; Pizza C; Manzione L
Ann Oncol; 2001 May; 12(5):669-74. PubMed ID: 11432626
[TBL] [Abstract][Full Text] [Related]
27. High-dose infusional 5-FU in the treatment of advanced colorectal cancer: a summary of the European experience.
Wils JA
J Infus Chemother; 1996; 6(3):145-8. PubMed ID: 9229327
[TBL] [Abstract][Full Text] [Related]
28. Advanced colorectal cancer: quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil.
Bogliolo G; Pannacciulli I; Desalvo L; Barsotti B; Lerza R; Mencoboni M; Arboscello E
Anticancer Res; 2000; 20(1B):501-4. PubMed ID: 10769713
[TBL] [Abstract][Full Text] [Related]
29. 5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial.
Breul J; Jakse G; Forster G; Lampel A; Rohani A; Hartung R
Eur Urol; 1997; 32(3):280-3. PubMed ID: 9358213
[TBL] [Abstract][Full Text] [Related]
30. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
Kundel Y; Purim O; Figer A; Stemmer SM; Tichler T; Sulkes J; Sulkes A; Brenner B
Med Sci Monit; 2008 Apr; 14(4):CR190-5. PubMed ID: 18376346
[TBL] [Abstract][Full Text] [Related]
31. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
Cao S; Frank C; Rustum YM
J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
[TBL] [Abstract][Full Text] [Related]
33. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
34. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
[TBL] [Abstract][Full Text] [Related]
35. Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin.
Préfontaine M; Donovan JT; Powell JL; Buley L
Gynecol Oncol; 1996 May; 61(2):249-52. PubMed ID: 8626142
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
Rossi A; Rosati G; Colarusso D; Manzione L
Oncology; 2003; 64(4):353-60. PubMed ID: 12759532
[TBL] [Abstract][Full Text] [Related]
39. 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
Hejna M; Kornek GV; Raderer M; Valencak J; Weinländer G; Fiebiger W; Miholic J; Scheithauer W
Ann Oncol; 1998 Dec; 9(12):1309-14. PubMed ID: 9932161
[TBL] [Abstract][Full Text] [Related]
40. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site.
Culine S; Ychou M; Fabbro M; Romieu G; Cupissol D
Anticancer Res; 2001; 21(2B):1455-7. PubMed ID: 11396231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
